PharmaTher's Preclinical Trial For Ketamine Micro-Needle Patch Shows Positive Results For Dosing

Ketamine-producer PharmaTher Holdings Ltd. PHRRF has successfully completed research evaluating its patented hydrogel-forming microneedle patch, PHARMAPATCH, to deliver ketamine and KETABET (ketamine and betaine anhydrous). 

The combination aims to study the possibility of preventing potential side effects of repeated ketamine treatment for depression and other indications (such as suicidal ideation, substance abuse, PTSD, neurological disorders and chronic pain), by studying the potential of desired dosage forms and pharmacokinetic profiles.

The company will next engage in preclinical studies to demonstrate delivery, dosing and safety profiles of ketamine in a comparable animal model to support regulatory filings to eventually conduct human clinical studies in Q4-2022 for treatment-resistant depression and pain.

Proprietary And Study Details

PharmaTher’s microneedle patch has proven to successfully deliver the dissociative hallucinogen esketamine, which may overcome the drawbacks associated with ketamine administration in an intravenous or nasal spray format. 

Led by Prof. Ryan Donnelly at Queens University Belfast, the study sought to develop and characterize PHARMAPATCH for sustained and safe transdermal delivery of ketamine and KETABET and closing production scale-up processes for clinical tests. 

The in vitro technique was used for the characterization of drug recovery and stability before drug permeation from films via hydrogel-forming microneedle array patches. Based on those findings, lead patches formulations were selected for in vivo testing on rats to assess their ability to achieve sustained plasma concentrations of ketamine and betaine within the therapeutic range for potential antidepressant therapy over the course of 48 hours.

The hydrogel-forming patch-mediated delivery of ketamine and betaine were compared with intramuscular injection and orally administered solution. 

Ultimately, blood sample results showed that PHARMAPATCH was able to deliver plasma levels of ketamine (between 70-200 ng/mL) in a controlled manner throughout the study.

This delivery system’s high degree of flexibility would supply effective treatment regimens beyond 48 hours, with further alterations in surface area, application time, and drug loading of the patches.

More On Microneedle Intradermal Drug Delivery

The method provides an efficient and painless way of increasing the skin permeation of many drugs, including ketamine. 

PharmaTher‘s current ketamine approach consists of a drug reservoir placed on top of the hydrogel microneedle array. After administration into the skin, the microneedles become hydrated and swell, creating pores for the reservoir to release the drug into the tissue over the treatment course. 

As shown by studies, the transdermal delivery provides drug concentrations in the system within minutes after administration and is maintained over multiple days. 

A highlight offered by this administration system is that it includes patients with pre-existing conditions that keep them from oral or inhalation dosing. 

Photo Courtesy of Unsplash.

Posted In: EsketamineProf Ryan DonnellyCannabisNewsPenny StocksPsychedelicsMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.